- $1.12bn
- $934.72m
- $239.44m
Proxy advisory firm ISS recommends STAAR Surgical investors reject Alcon deal (updated)
Proxy advisory firm ISS recommends STAAR Surgical investors vote down Alcon deal
Brief: Broadwood Partners Questions STAAR Board's Diligence In Reaffirming Support For Alcon Sale
Brief: Staar Surgical Board Urges Stockholders To Vote “For” Alcon Merger
Brief: Broadwood And Glass Lewis Urge STAAR Shareholders To Vote “Against” Sale To Alcon
Brief: Broadwood Partners Continues To Urge STAAR Shareholders To Vote "Against" Proposed Transaction By Alcon
Brief: Defender Capital Opposes Staar Surgical's Proposed Sale To Alcon
Brief: Yunqi Capital, One Of Staar Surgical Company’S Largest Shareholders, Reiterates Its Opposition To The Proposed Merger With Alcon
Brief: Broadwood Urges Shareholders To Vote Against Proposed Acquisition Of STAAR By Alcon
Brief: Staar Surgical Co Board Of Directors Strongly Encourages All Stockholders To Vote "For" Alcon Merger
Brief: Broadwood Partners - Publishes Presentation Detailing Opposition To Staar Surgical's Sale To Alcon
Brief: Alcon And Staar Surgical Announce Expiration Of Hart-Scott-Rodino Waiting Period For Alcon’S Acquisition Of Staar
Brief: Staar Surgical Publishes Presentation Highlighting Value Offered By Alcon Merger, Downside Risks If Merger is Not Approved
Brief: Corrected-Broadwood Partners Says Staar Surgical Deal Delivers Less Value Than Alternatives
Brief: STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
Brief: STAAR Surgical Board Of Directors Unanimously Believes Alcon Merger Maximizes Value For STAAR Stockholders
Brief: STAAR Surgical Reiterates Compelling, Premium Cash Value Provided By Alcon Merger
STAAR shareholder Broadwood says it opposes Alcon's proposed takeover (updated)
Brief: Broadwood Announces Intent To Vote Against Acquisition Of Staar Surgical By Alcon